Everolimus Treatment in a Neonate with Heart Failure Caused by Cardiac Rhabdomyomas
Department of Pediatrics, Juntendo University Faculty of Medicine ◇ Tokyo, Japan
Department of Pediatrics, Juntendo University Faculty of Medicine ◇ Tokyo, Japan
Most primary pediatric cardiac tumors are rhabdomyomas, which are generally associated with tuberous sclerosis complex. Large tumors can sometimes cause heart failure, and surgery might be required for patient survival. Everolimus, an oral mammalian target of rapamycin inhibitor, has been recently studied for its antineoplastic effect. Here, we describe a case involving successful everolimus treatment for cardiac rhabdomyomas in a neonate.
Key words: everolimus; tuberous sclerosis complex; cardiac rhabdomyoma
© 2019 特定非営利活動法人日本小児循環器学会© 2019 Japanese Society of Pediatric Cardiology and Cardiac Surgery
This page was created on 2019-05-31T13:40:43.644+09:00
This page was last modified on 2019-07-02T13:33:26.000+09:00
このサイトは(株)国際文献社によって運用されています。